| Name | Title | Contact Details |
|---|---|---|
Todd Spaulding |
VP Product Management | Profile |
Denville Scientific is a Metuchen, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Shockwave Medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. Inspired by 30-years of safety and efficacy in kidney stone treatment, our Intravascular Lithotrispy family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. IVL catheters use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. An integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. In peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, IVL demonstrated safety and consistent procedure success with low procedural complications. The technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatments. And because it is built on a traditional balloon catheter platform, it integrates seamlessly with clinicians` existing workflow.
Sunrise Medical Technology is a Waxahachie, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Thar Technologies is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Smith & Nephew is a global advanced medical technology business. We support healthcare professionals in more than 100 countries to improve the quality of life for their patients. Since 1856, when our founder T.J. Smith developed a new method for refining cod liver oil, and in World War One when his nephew led the supply of wound care products, to the present day, Smith & Nephew continues to pioneer health solutions. Through our market leadership positions in Sports Medicine, Trauma, Orthopaedic Reconstruction and Advanced Wound Management, our 16,000 employees continue to improve outcomes and expand access, constantly striving to create value for healthcare professionals, patients, payers and shareholders. Annual sales in 2016 were more than $4.6 billion. We are a constituent of the UK’s FTSE100 and our shares are traded on London Stock Exchange and through American Depository Receipts on the New York Stock Exchange We have leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma. We have almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2013 were more than $4.3 billion. We are a constituent of the UK's FTSE100 and our shares are traded on the London Stock Exchange and through American Depository Receipts on the New York Stock Exchange (LSE: SN, NYSE: SNN)